Diclofenac does not modify morphine bioavailability in cancer patients

Franco De Conno, Carla Ripamonti, Mauro Bianchi, Vittorio Ventafridda, Alberto E. Panerai

Research output: Contribution to journalArticlepeer-review


We determined morphine plasma concentrations in 6 cancer patients before and with administration of diclofenac for 5 days. The non-steroidal anti-inflammatory drug does not modify morphine bioavailability. This observation suggests that diclofenac can be used in association with morphine during cancer pain treatment, without increasing the risk of overdosage or side effects of the opiate.

Original languageEnglish
Pages (from-to)401-402
Number of pages2
Issue number3
Publication statusPublished - 1992


  • Bioavailability
  • Diclofenac
  • Morphine

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Pharmacology
  • Clinical Psychology


Dive into the research topics of 'Diclofenac does not modify morphine bioavailability in cancer patients'. Together they form a unique fingerprint.

Cite this